Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis

BACKGROUND: Inhibitors of programmed cell death-1 (PD-1) and its ligand (PD-L1) have represented a novel approach for the management of advanced non-small cell lung cancer (NSCLC). In this study, we aimed to estimate five anti-PD-1/L1 agents (nivolumab, pembrolizumab, atezolizumab, durvalumab, and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jiaqi, Li, Ming, Sui, Qihai, Hu, Zhengyang, Bian, Yunyi, Huang, Yiwei, Zhan, Cheng, Jiang, Wei, Wang, Qun, Tan, Lijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481633/
https://www.ncbi.nlm.nih.gov/pubmed/32953506
http://dx.doi.org/10.21037/tlcr-20-192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481633/
https://www.ncbi.nlm.nih.gov/pubmed/32953506
http://dx.doi.org/10.21037/tlcr-20-192

Ejemplares similares